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1. Introduction 
Benign Prostate Hyperplasia (BPH) is a common disease in adult men and its incidence is 
age related. On the basis of clinical criteria, the Baltimore Longitudinal Study of Aging 
found that the prevalence of BPH is approximately 25% in men aged 40 to 49 years, 50% in 
men aged 50 to 59 years, and 80% in men aged 70 to 79 years (Arrighi, Metter et al. 1991). 
BHP is theoretically the detection of prostatic hyperplasia, which is the benign proliferation 
of the stroma and epithelium, by histological study. However histological studies for all 
men are unfeasible in clinical practice, so BHP usually refers to the palpable enlargement of 
the prostate, which can be detected by clinical or ultrasonographic examination, or presence 
of urinary symptoms loosely defined as lower urinary tract symptoms (LUTS), which are 
usually classified as obstructive or irritative (Levy and Samraj 2007). 
Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic 
processes associated with abnormal kidney function, and a progressive decline in 
glomerular filtration rate (GFR). Chronic renal failure (CRF) applies to the process of 
continuing significant irreversible reduction in nephron number, end-stage renal disease 
(ESRD) represents a stage of CKD where the accumulation of toxins, fluid, and electrolytes 
normally excreted by the kidneys results in the uremic syndrome. This syndrome leads to 
death unless the toxins are removed by renal replacement therapy, using dialysis or kidney 
transplantation (Fauci 2007). The prevalence of CRF using the Modification of Diet in Renal 
Disease equation is 26% in adults who are 70 years and older.  Men are at 67% greater risk 
for advanced chronic renal failure and at 44% greater risk for end stage renal disease than 
women (Rule, Lieber et al. 2005). 
Despite the many possible causes of obstructive uropathy, in studies of elderly patients with 
acute renal failure, the most common cause among all patients was BPH (Kumar, Hill et al. 
1973; Tseng and Stoller 2009). Kumar et al., showed in their studies that acute renal failure in 
patients with obstructive uropathy were due to BPH (38%), neurogenic bladder (19%), 
obstructive pyelonephritis (15%).  
Attending to high prevalence of BPH in older men with CKD it is invaluable to take into 
consideration the relationship between these two clinical entities. However, despite the high 
prevalence of CKD and BPH in elderly men, there is limited knowledge on the association 
between these two conditions. 
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The purpose of this chapter is to discuss the relationship between BPH and CKD, bearing in 
mind the epidemiology, pathophysiology, the clinical and imagiologic presentation of BPH 
and how it can contribute to CKD.  
2. Epidemiology – Benign prostatic hyperplasia and chronic kidney disease 
Benign prostatic hyperplasia is characterized by the nonmalignant overgrowth of prostatic 
tissue surrounding the urethra, ultimately constricting the urethral opening and giving rise 
to associated lower urinary tract symptoms (McVary 2006; Wei, Calhoun et al. 2008).  
Diagnosis of BPH is made based on histologic examination of a prostatic tissue (biopsy, 
surgery or autopsy), however surrogate measures, namely lower urinary symptoms, 
bladder outlet obstruction and prostate enlargement are often used to define BPH as a 
clinical syndrome (Emberton, Andriole et al. 2003). For this reason, many consequences of 
BPH are not studied for it is impractical. This factgives us limited insight into the incidence 
and progression of the disease (Jacobsen, Girman et al. 2001). The prevalence of BPH thus 
can be calculated on the basis of histologic criteria (autopsy prevalence) or clinical criteria 
(clinical prevalence) (Wein 2007).  
The 1984 milestone study by Berry and colleagues summarized the data from five studies 
demonstrating that no men younger than 30 had evidence of BPH and the prevalence rose 
with each age group, peaking at 88% in men in their 80s (Berry, Coffey et al. 1984).  
BPH is considered a disease of aging male and can have a familial inheritance, especially if 
large prostate volumes and surgical intervention at a young age are seen in the pedigree 
(Wein 2007). 
Definitions of BPH, have undergone several changes in the past decade, and, at present, no 
single criterion can be applied. In the past, the term "prostatism" was used, incorrectly 
referring to the prostate as the sole source of the typical LUTS (lower urinary tract 
symptoms) found in aging men. It has been pointed out that there are at least three 
interrelated phenomena that can be assessed independently, namely the symptoms (Wein 
2007), enlargement of the prostate gland and presence of obstruction (Nielsen, Nordling et 
al. 1994). In a given patient, all three, two of the three, or only one of the three entities might 
be present. Paul Abrams was the investigator that changed the earlier and  inappropriate 
term (prostatism) to lower urinary tract symptoms (LUTS) (Nielsen, Nordling et al. 1994; 
Abrams 1999) 
BPH (histologically) is present in about 8% of men aged 31 to 40 years, and this prevalence 
increases markedly with age to about 90% by ninth decade(Berry, Coffey et al. 1984; Rosen, 
Altwein et al. 2003; McVary 2006). Studies in United States, England, Austria, Norway, 
Denmark, China, Japan, and India showed that the prevalence of BPH increases rapidly in 
the fourth decade of life, reaching nearly 100% in the ninth decade (Harbitz and Haugen 
1972; Carter and Coffey 1990; Wein 2007) (Pradhan and Chandra 1975). It is striking that the 
age-specific autopsy prevalence is remarkably similar in all populations studied regardless 
of ethnic and geographic origin (Berry, Coffey et al. 1984). 
However, we must take into account the aging population and increasing number of 
patients who need medical care for symptoms (LUTS) or consequences of BPH. Number of 
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consultations for BPH and urinary symptoms constitute the largest share of visits in our 
department and in urology departments worldwide. In 1989, there were approximately 1,3 
million office visits to physician for BPH (Schappert 1993), and in 1992 approximately 
170.000 prostatectomies were performed among inpatients in the United States (Xia, Roberts 
et al. 1999; Wei, Calhoun et al. 2008). Agency for Health Care Policy and Research 
Diagnostic and Treatment for BPH showed that from 22.5 million white men aged 50 to 79 
years in the United States, in 1990, approximately 5.6 million needed medical consultation 
and treatment for BPH, demonstrating this disease is a prevalent health problem (Wei, 
Calhoun et al. 2008). 
Although BPH is not a life-threatening condition, the impact of BPH on quality of life (QoL) 
can be significant and should not be underestimated (McVary 2006). According to the World 
Health Organization although the death rate attributable to BPH is negligible, the estimated 
DALY’s (The sum of years of potential life lost due to premature mortality and the years of 
productive life lost due to disability) due to BHP is quite considerable. Most of the disability 
is probably due to severe clinical symptoms and/or late complications of BPH like CKD 
(Organization 2011). 
Chronic kidney disease is a serious condition associated with premature mortality, 
decreased quality of life, and increased health-care expenditures. Untreated CKD can result 
in end-stage renal disease requiring  dialysis or kidney transplantation. 
The 1999-2004 National Health and Nutrition Examination Survey (NHANES) determined 
that 16.8% of the U.S. population aged >20 years had CKD (according to 1999-2004 data), 
compared with 14.5% from the 1988-1994 NHANES, an increase of 15.9% based on crude 
estimates of prevalence (Saydah 2007) which reflects the increasing needs for health care 
policy for CKD. 
3. The relationship between benign prostatic hyperplasia and chronic kidney 
disease – A consequence of urinary outflow obstruction? 
Although the exact etiology of BPH is not known it seems (from recent studies and daily 
clinical practice) that the natural history and evolution of benign prostatic enlargement ends 
up in urinary obstruction causing degradation of renal function over time.  
Both diseases are extremely common among aging male, leading some to suggest that it is a 
natural concomitant of aging (Wu, Li et al. 2006). 
In his 1989 retrospective study of 19 patients who were admitted to renal dialysis units for 
end-stage renal disease caused by BPH, authors (Sacks, Aparicio et al. 1989) raised 
awareness of BPH as a cause for CKD and suggested a more adequate screening of renal 
function in men with untreated LUTS. More recently a cross-sectional survey in Spain of 
2,000 randomly sampled men who were 50 years or older showed a 2.4% prevalence of 
self-reported renal failure related to a prostate condition (9% reported renal failure from 
any cause) (Hunter, Berra-Unamuno et al. 1996; Rule, Lieber et al. 2005).  The main 
limitation of this study was that it relied on the self report of CKD, and no distinction 
between Acute Renal Failure (ARF) or CKD was made. Nonetheless it remains one largest 
studies that reveals a connection between CKD and BPH (Hunter, Berra-Unamuno et al. 
1996). Another study (Hill, Philpott et al. 1993) showed that men presenting for prostate 
www.intechopen.com
 Chronic Kidney Disease 350 
surgery had a 7,7% prevalence of renal failure compared to a 3,7% prevalence in age 
matched men presenting for nonprostate surgery. This proves that renal failure in men 
with advanced BPH does not only reflect older age.  Other statistical study revealed that 
men presented to urologist for BPH treatment showed an average of 13,6% of renal 
failure(McConnell, Barry et al. 1994).  
The Rochester Epidemiology Project found a significant association between signs and 
symptoms of BPH and CKD in their population-based sample of 476 white men (Rule, 
Jacobson et al. 2005; Rule, Lieber et al. 2005). There was a significant association between 
CKD and moderate/ severe LUTS and peak flow rate of <15 mL/s. In conclusion there was 
a cross-sectional association between signs and symptoms of bladder outlet obstruction and 
chronic kidney disease in community-dwelling men (Rule, Lieber et al. 2005).  
In contrast, a population-based study from Austria did not find LUTS to be an independent 
risk factor for impaired kidney function in men. A total of 2.469 men entered the cross-
sectional study and 439 with CKD were assessed in longitudinal analysis. LUTS was 
assessed using the IPSS (International Prostate Symptom Score) questionnaire. There was no 
significant association between degree of LUTS and GFR after adjusting for age in this cross-
sectional study (Ponholzer, Temml et al. 2006). 
Furthermore a 30,466 men study from the HUNT II (Second Health Study in Nord-
Trøndelag; 1995-1997) failed to show a connection between LUTS and CKD (Hallan, Kwong 
et al. 2010).  Results have shown that men with moderate to severe LUTS, indicating BPH, 
did not have increased risk of future kidney failure after adjusting for age, and inclusion of 
men with such symptoms did not improve the effectiveness of a CKD screening strategy 
using kidney failure as the main outcome (Hallan, Kwong et al. 2010; Hallan and Orth 2010).  
Nonetheless quite recently evidence of association between BPH and CKD has arisen in two 
different studies. In a recent study by Yamasaki et al, the Post-Void Residue (PVR) of the 
patients with CKD was significantly greater than that of the patients without CKD and the 
presence of post-void residual urine was independently associated with CKD, indicating a 
close association between CKD and residual urine.  In this study the PVR is used as a 
surrogate measure of Bladder Outlet Obstruction (BOO) and thus of urodinamically 
relevant  BPH (Yamasaki 2010). Authors reported a higher prevalence (31,8%) of CKD 
among BPH patients (Yamasaki 2010). In another study by Hong et al (Hong, Lee et al. 
2010), the results showed that a decreased Qmax (Peak flow rate), with a history of 
hypertension and/or diabetes, were significantly associated with CKD in men seeking 
management for LUTS caused by BPH of various severity. Although the prevalence of CKD 
can be considered relatively low among men with BPH, the possibility of CKD should be 
considered in those who have a low Qmax, obstructive urinary symptoms, or have 
comorbidities such as hypertension and DM (Hong, Lee et al. 2010).  In this study the 
authors report 494 patients from a group of 2741 BPH patients that were classified as having 
CKD (eGFR < 60 mL/min/1,73 m2).   
The 1994 Agency for Health Care Policy and Research created BPH clinical guidelines that 
recommended serum creatinine screening in men presenting with lower urinary tract 
symptoms, however a 2003 update discontinued the serum creatinine measurements (Rule, 
Lieber et al. 2005). These different approaches to BPH patients may lead to a significant 
amount of patients underdiagnosed for CKD.  
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As we take all this data into account, one should bear in mind that BPH is an almost 
ubiquitous condition in the old man. The low occurrence of CKD in BPH clinical trials 
should not be used to infer a weak association between the two disease processes.  However 
it is clear that not all expressions of BPH are associated with CKD: Prostate volume, PSA 
(Prostate Specific Antigen) and even LUTS do not share a strong association with CKD 
(Rule, Jacobson et al. 2005; Ponholzer, Temml et al. 2006; Hallan, Kwong et al. 2010).  
Bladder outlet obstruction signs and symptoms (QMax, PVR, Obstructive LUTS) are 
significant predictors of CKD (Rule, Jacobson et al. 2005; Yamasaki 2010), bladder outlet 
obstruction probably makes the bridge between CKD and BPH (Hong, Lee et al. 2010). This 
is probably a reflection of the etiology of CKD secondary to BPH.  
We should also never forget that CKD is a multifactorial process, and it becomes difficult 
to separate the contribution of BHP from all the other renal insults. This also takes its toll 
on the design of the studies as many men with concomitant disease are excluded, and 
thus making it harder for investigators to take into account the true influence of BPH on 
CKD. 
4. BPH physiopathology, disease progression and renal failure 
The exact etiology of BPH is unknown, however the similarity between BPH and the 
embryonic morphogenesis of the prostate has led to hypothesis that BPH may result from a 
reawakening of embryonic  induction process  in adulthood (Oesterling 1996; McVary 2006). 
The most common renal pathology finding in men with obstructive nephropathy due to 
BPH is chronic interstitial nephritis (Coroneos, Assouad et al. 1997; Rule, Lieber et al. 2005) 
and 30% of cases have been attributed to obstructive uropathy.  
Late or end stage renal failure secondary to prostatic or bladder outflow obstruction should 
be amenable to prevention if cases are recognised early, however it still difficult to recognise 
which men with BPH are at risk of renal failure and need close investigation. For this reason 
we truly believe that is important to recognize factors that can be measured and are 
important bases or risk factors for the evaluation and treatment of BPH. 
To assess BPH as risk factor for chronic kidney disease or renal failure it is important to 
understand the surrogate measures often used to diagnose BPH. These factors are 
essentially clinical, anatomical and physiological.  
4.1 Benign prostate enlargement 
BPH/BPE first develops in the periurethral transition zone of the prostate. The transition 
zone consists of two separate glands immediately external to the preprostatic sphincter. 
Prostate enlargement also involves an increase in the number of glands, particularly the 
periuretheral glands, and increase in smooth muscle and connective tissue in the 
periuretheral region of the prostate (McNeal 1978; Rule, Lieber et al. 2005; Wein 2007). 
Prostate size can be estimated by digital rectal examination (DRE) (underestimate true 
prostate size) but reliability across observers is in general considered poor (Wein 2007), for 
these reasons in all cross-sectional studies prostate volume is assessed by TRUS (trans-rectal 
ultrasound).  
www.intechopen.com
 Chronic Kidney Disease 352 
In the physiological point of view, as the prostate enlarges, it compresses the urethra, 
preventing the outflow of urine and contributing to the common lower urinary tract 
symptoms. 
Previous studies which examined the association between prostate size and renal function 
gave conflicting results (Rule, Lieber et al. 2005), some showing a strict relation between 
prostate size and GFR (Olbrich, Woodford-Williams et al. 1957)  but other studies did not 
(Terris, Afzal et al. 1998) 
Other authors, like Shapiro et al. emphasize the role of prostatic smooth muscle in 
pathophysiology of BPH (Shapiro, Hartanto et al. 1992). These authors advocated that the 
amount of muscle in prostate size and its contractile properties are an important factor in BPH. 
Smooth muscle cells in are not optimal for force generation. They present a downregulation of 
smooth muscle myosin heavy chain and a significant  upregulation of nonmuscle myosin 
heavy chain, suggesting either proliferation or loss of normal modulation pathways (Lin, 
Robertson et al. 2000). Factors that determine passive tone in prostate remain to be elucidated 
(Wein 2007). However it is known that active muscle tone in human prostate is regulated by 
adrenergic nervous system (Schwinn 1994). Adrenergic neurotransmitters have been involved 
in prostate smooth muscle regulation as well as contraction, and ǂ-adrenergic blockade leads 
to a significant downregulation of normal protein gene expression, specifically smooth muscle 
myosin heavy chain (Boesch, Dobler et al. 2000; Wein 2007). 
Recent studies were made to relate prostate size and LUTS in BPH. Hassanzadeh et. al,  
found a significant correlation between urgency and  prostate size (Hassanzadeh, Yavari-kia 
et al. 2010), which can be considered as predictive factor for the disease and probably a 
strong link between BPE and CKD.  
So, prostate and its enlargement can contribute for outflow obstruction not only by is static 
component (periurehral compression caused by stromal component) but also dynamic 
component (smooth muscle cells and adrenergic pathway).  Prostate growth is only one of 
the components of LUTS in aging men. 
4.2 Lower Urinary Tract Symptoms (LUTS) 
Lower urinary tract symptoms (LUTS) are clinical criteria to define a man with urinary 
problems. Most of the men with BPH have voiding dysfunction, complaining with nocturia, 
urgency, week urinary stream, increased urinary frequency and sense of incomplete bladder 
emptying after micturition.  
Many studies were done to achieve a scientific relation between LUTS and CKD, however 
until recent years there was no palpable evidence connecting these two entities. Hill et al. in 
a retrospective study did not find any relation between duration of symptoms and serum 
creatinine levels (Hill, Philpott et al. 1993). Likewise Gerber et al. did not achieve any success 
in linking serum creatinine levels and LUTS (Gerber, Goldfischer et al. 1997). Hong et al., 
reported that although there was no significant association between overall symptoms (IPSS 
score) with CKD, individual obstructive symptoms such as hesitancy and/or weak stream 
was significantly associated with CKD status (Hong, Lee et al. 2010) 
Our clinical practice shows us that many men with LUTS do not value their symptoms, and 
do not seek medical care. Those older men often tolerate and disregard their lower urinary 
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tract symptoms. In our opinion under reported symptoms can induce a significant bias in 
most of studies already done.  
Although many patients who do not value their symptoms, mainly the older ones, the 
frequency of symptoms and its interference with quality of live (QoL) is the  principal factor 
that drive men to consult a physician (Hong, Rayford et al. 2005).  
Patient perceptions are receiving greater emphasis as part of clinical decision-making 
(Jacobsen, Guess et al. 1993; Roberts, Rhodes et al. 1994). The variability of relationships 
between symptom severity and the likelihood that the symptoms relate with CKD requires 
further investigations. However one must take into account that the absence of lower 
urinary tract symptoms in older man does not necessarily exclude BPH with urinary outlet 
obstruction. Moreover, whether symptoms can be graded according to severity 
(International Prostate Symtpoms Score – IPSS) this does not predict the degree of 
obstruction to urinary flow. However, when men with complete chronic urinary retention 
and severe symptoms needing surgical intervention were evaluated, the authors found as 
much as 30% of men with renal insufficiency (Sacks, Aparicio et al. 1989). 
4.3 Post-voiding residual urine volume – Chronic urinary retention  
Chronic  urinary retention is thought to be the dominant mechanism by which BPH can 
cause chronic renal failure (Rule, Lieber et al. 2005). Rule et al, defined chronic urinary 
retention (CUR) as a post-void residual urine (PVR) higher than 100 mL, and reported that  
CUR was significantly associated in CKD in community-dwelling men. For years it has been 
well described that large volumes (»300 mL) affect renal function in advanced BPH (Styles, 
Neal et al. 1988; Rule, Lieber et al. 2005; Yamasaki 2010). 
Recent studies, however, demonstrate that the volume of residual urine (post void) 
necessary to impair renal function is not that elevated. Yamasaki et al, verified in their study 
a cut-off of 12 ml for PVR (Yamasaki 2010), confirming PVR as a significant and 
independent risk factor for CKD. This study showed for the first time that patients with 
BPH can develop impaired renal function with small amounts of post-void urine (PVR< 100 
ml). Furthermore, these findings indicated a higher prevalence of CKD in patients with 
BPH, acknowledging it as a risk factor for CKD. However, the mechanism by which small 
PVR influence renal function remains unknown. 
Although, as Yamasaki et al. demonstrated low post-void residual urine can cause 
deterioration of renal function it is scientifically accepted that large residual pos-void urine 
are in line more severe cases of renal function deterioration (Yamasaki 2010). 
4.3.1 Acute urinary retention  
Acute urinary retention (AUR) is defined as an acute complication of benign prostatic 
hyperplasia, patients suffers from an acute, sudden and painful inability to micturate. AUR 
represents an immediate indication for intervention or even surgery. Between 25% and 30% 
of men who underwent transurethral resection of prostate (TURP) had AUR as their main 
indication (Wein 2007). This complication is not exclusive for patients suffering from BPH, 
other causes can trigger acute urinary retention, like surgery, anaesthesia, trauma, 
medications, medical examination and urinary tract infections (mainly prostatitis).  
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In 2002 the self-reported rate of AUR in a cross sectional study in Spanish men was 5.1% 
(Hunter, Berra-Unamuno et al. 1996).  
Acute urinary retention is not common in men under sixty years, and may be responsible 
for the majority of acute renal failure cases due to obstructive uropathy (Prakash, Saxena et 
al. 2001). Men in whom acute urinary retention is promptly relieved by bladder 
catheterization acute renal failure does not develop but long-term tubular  dysfunction may 
still occur (Rule, Lieber et al. 2005).  It is believed that acute urinary retention without prior 
history of chronic urinary retention do not lead to chronic renal failure. High bladder 
compliance allows men to maintain a normal GFR, however renal tubular dysfunction may 
persist after the acute urinary retention episode and probably result in progressive renal 
disease.  
4.4 Bladder remodelling – Bladder response to urinary obstruction  
The bladder has a central role in pathophysiology of BPH and its complications. 
Current evidence suggests that the bladder´s response to obstruction is largely an adaptative 
one, although it is only a partially adptative one. It is also clear for many authors and 
physicians that LUTS in men with BPH or prostate enlargement are more closely related to 
obstruction-induced changes in bladder function than to the outflow obstruction directly.  
There are of two types of bladder changes. First, changes that lead to detrusor instability 
(clinically associated with symptoms of frequency and urgency). Second, changes associated 
with decreased detrusor contractility (emptying symptoms – low urinary stream, hesitancy, 
intermittency, increased residual urine) and detrusor failure (Wein 2007).  
The development of bladder wall thickening (easily measurable by ultrasound) and 
trabeculation due to smooth muscle hypertrophy and connective tissue permeation is 
responsible for increased bladder pressure in patients with high pressure chronic retention 
(Jones, Ellis et al. 1991; Rule, Lieber et al. 2005). Gosling et al, were some of the first authors 
who established endoscopically that major detrusor changes and trabeculation were due to 
an increase in detrusor collagen (Gosling and Dixon 1980). Severe trabeculation is related to 
significant residual urine, suggesting that increased collagen in the bladder wall is probably 
responsible for incomplete bladder emptying to rather than impaired muscle function (Wein 
2007). Detrusor hypertrophy is one of the first modifications in the bladder and, as in animal 
models, the initial response is the development of smooth muscle hypertrophy (Gosling, 
Kung et al. 2000; Levin, Haugaard et al. 2000). This is an adaptative response associated with 
intra and extracellular changes in the smooth muscle cells that leads to detrusor instability. 
Obstruction also induces changes in smooth muscle cells contractile protein expression, 
impairing cell-to-cell communication (Levin, Haugaard et al. 2000), with changes in myosin 
heavy chain isoform expression (Lin, Robertson et al. 2000) that lead to detrusor instability 
and in some cases to impaired contractility (Wein 2007).  
Cellular and physiological changes in bladder muscle and collagen, contribute to a high 
pressure bladder that perpetuates itself with worsening ability to empty and causing kidney 
lesions.  
These mechanisms of bladder remodelling develop in a hypofunctional bladder, with low 
compliance. Comiter et al. reported that in a series of men with symptomatic BPH, 78% of 
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patients with low bladder compliance had renal failure (Comiter, Sullivan et al. 1997). Low 
bladder compliance and detrusor instability may be causal mechanisms for renal failure in 
men in chronic urinary retention (Rule, Lieber et al. 2005). 
In other studies (animal experimental studies) in addition to obstruction-induced changes in 
the smooth muscle cell and collagen of the bladder wall, there was clear evidence that 
obstruction may modulate neural-detrusor responses, causing reduced bladder contractility 
and altered sensation (Chai, Andersson et al. 2000) 
Bladder remodelling is a response to continued bladder obstruction, and detrusor smooth 
muscle cell is a key contributor to the complex symptoms associated with prostatic 
obstruction (Christ and Liebert 2005), namely in BPH/BPE (benign prostatic enlargement).   
4.5 Ureterovesical junction  and upper tract dilation  
In general, ureterovesical junction obstruction caused by bladder remodelling in chronic 
urinary retention is a contributing mechanism for renal failure in BPH (Rule, Lieber et al. 
2005). Upper tract dilation occurs as a consequence of a continuum bladder outlet 
obstruction and remodelling (detrusor hypertrophy and scarring) leading to anatomical 
ureterovesical junction obstruction (Jones, Ellis et al. 1991). Upper urinary tract dilation or 
hydronephrosis is consistent with chronic renal failure from obstructive uropathy. In men 
with BPH and increased serum creatinine,  hydronephrosis is common (one third), and is 
found in 90% of men with BPH who are hospitalized for uremic symptoms (Sacks, Aparicio 
et al. 1989). In ultrasound evaluation it is common among patients with bilateral 
hydroureteronephrosis to observe compressing and thinning of renal cortex, with obvious 
impact in renal function. A history of enuresis, painless chronic retention, and palpable 
bladder should suggest a diagnosis of high pressure chronic retention with its attendant risk 
of hydroureteronephrosis (Sacks, Aparicio et al. 1989). 
4.6 Other causes 
Recurrent urinary tract infections in men with chronic urinary retention due to BPH may 
also contribute to chronic renal failure (Rule, Lieber et al. 2005).  
Secondary hypertension due to chronic urinary retention is also a described complication of 
BPH, leading to hypertensive kidney disease (Ghose and Harindra 1989). 
Nephrogenic diabetes insipidus caused by partial or chronic urinary obstruction can result 
in renal failure (Klahr 2001).  
Other clinical entities like diabetes and hypertension are independent factors that can lead to 
CKD (Gerber, Goldfischer et al. 1997). Patients with BPH are probable carriers of these 
pathologies that are likely to seriously aggravate renal function and must be taken into 
account as sombre conditioners of renal disease.  
5. Clinical presentation 
BPH is a chronic and progressive condition (Jacobsen, Girman et al. 2001)  patients  
generally have a history of lower urinary tract symptoms and indolent obstructive 
uropathy. 
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Clinical presentation of BPH/obstructive uropathy varies and reflects the source and 
duration of obstruction. In BPH, symptoms results from the direct bladder outlet 
obstruction (BOO) from enlarged tissue (static component) and the increased smooth muscle 
tone and resistance within the enlarged gland (dynamic component). This physiologic issues 
reflect in voiding dysfunctions, that significantly affects the health and quality of life of 
many older men.  
Most of the patients have characteristic symptoms. Patients’ complaints are usually nocturia, 
urgency (imperious will to hold urine, some with complaints of incontinence), weak urinary 
stream (with decreased flow rate, low values in Qmax and Qaverage), a sense of incomplete 
bladder emptying, straining during micturition, increased micturition frequency and 
dribbling during or after urination (Rule, Lieber et al. 2005). Physical examination consists in 
a digital rectal examination (evaluating prostate characteristics and volume) and lower 
abdominal percussion and palpation to assess for bladder distension.  
Recurrent or persistent urinary tract infections (UTI) are associated with prolonged urinary 
stasis of lower urinary tract obstruction, dysuria, frequency, urgency and hematuria are 
common complaints among men with UTI.  
Chronic urinary retention as consequence of BPH has been defined as a palpable bladder 
that corresponds to a high PVR (Neal 1990), and most of the patients with chronic urinary 
retention have an indolent and progressive disease, with worsening of urinary symptoms 
and the majority of these patients just seek for medical care in bad health conditions with 
sharp renal insufficiency. It is always necessary to investigate symptoms and signs of 
chronic renal failure – nausea, vomiting, lethargy, edema and hypertension, that occur at 
late stage, usually with irreversible renal damage (Sacks, Aparicio et al. 1989), principally in 
older patients with other comorbidities (mainly diabetes and hypertension). In rare cases 
patients who resort to the emergency room because of anuria, require interventional 
procedures like indwelling catheter, nephrostomy (uni or bilateral) and sometimes 
(depending the level of renal function) hemodialysis.   
Although signs and symptoms of BPH are normally present, there are a significant number 
of patients that are relatively asymptomatic (Tseng and Stoller 2009) (without significant 
voiding dysfunction), but can present primarily clinical sequel of renal insufficiency – 
uremia; with nausea, vomiting and mental status changes – and analytical changes – 
electrolyte disturbances (hypercaliemia and nonanion gap acidosis).  
Older patients with voiding dysfunctions caused by chronic urinary obstruction, might 
present hypertension due to hypervolemia in the case of bilateral obstruction or increased 
renin release (Tseng and Stoller 2009). Hypertension, on other hand can be itself the sole 
cause of renal failure.   
The development and validation (for different languages) of the standardized, self-
administered symptom index (International Prostate Symptom Score [IPSS]) has been a 
critical event in the clinical research on LUTS and BPH (Cockett, Barry et al. 1992; Wein 
2007). This diagnostic and follow-up tool is extraordinary, and the availability of validated 
translations in many common languages allows cross-cultural comparisons among man 
with BPH or LUTS from other causes.  
In addition the enumeration of symptoms by frequency and time of occurrence, the bother 
associated with the symptoms, interference with activities of daily living, and the impact the 
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symptoms have on quality of life are important in distinguishing characteristics that we 
must take into account in evaluation of BPH patients. (Wein 2007). 
Left untreated, BPH can cause serious  complications including renal failure can occur, as 
acute renal failure (discussed above), urinary tract infections, bladder stones, hematuria, 
incontinence and mortality related with BPH. 
5.1 Other complications of benign prostatic hyperplasia 
5.1.1 Mortality  
La Vecchia et al, reported that in the early 1980s, overall mortality from BPH ranged 
between 0,5 and 1,5/100 000 in most western European countries (La Vecchia, Levi et al. 
1995). Between the early 1950s and the late 1990s, the overall mortality from BPH in the 
European Union (EU) fell from 5.9 to 3.5 per million, and the decline since the late 1950s was 
over 96%. Comparable falls were observed in the USA and Japan, and BPH mortality rates 
in the late 1990s were lower than in the EU (1.8/10(6) in the USA, 1.4 in Japan). BPH 
mortality trends were downwards also in the Eastern Europe, although rates in the late 
1990s were about fourfold higher than in the EU (Levi, Lucchini et al. 2003). 
Recent works have proven decreasing mortality rates related with BPH. The fall in BPH 
mortality, evident in statistics on underlying cause, was confirmed by statistics on all 
certified causes of death. In England, underlying-cause mortality reduced from 9.2 deaths 
per million in 1995 to 4.5 deaths per million in 2006 (Duncan and Goldacre 2011). The fall is 
remarkable in scale, likely to be attributable to clinical care, and could be regarded as an 
indicator of improving standards of care (Duncan and Goldacre 2011).  
It is important to remember that patients in renal failure have an increased risk for 
complications following TURP compared with patients with normal renal function (25% 
versus 17%) (Holtgrewe, Mebust et al. 1989) and the mortality increases up to sixfold 
(Holtgrewe and Valk 1962; Melchior, Valk et al. 1974).  
5.1.2 Bladder stones 
In a large autopsy study the prevalence of bladder stones was eight times higher in men 
with a histological diagnosis of BPH (3.4%) than in control subjects (0.4%), but no increased 
incidence of ureteral or kidney stones was found (Grosse 1990). Bladder stones are in line 
with urinary retention, stasis and urinary infection, factors that propitiate ion aggregation 
and stone nucleation.  
5.1.3 Urinary tract infections  
In previous surgical series, urinary tract infections (UTIs) constitute the main indication for 
surgical intervention (12% of patients) (Holtgrewe, Mebust et al. 1989). Urinary tract 
infections are generally due to chronic urinary obstruction caused by increased amounts of 
residual urine, that predispose to UTIs (Mebust, Holtgrewe et al. 1989).  
5.1.4 Urinary incontinence 
Incontinence is one of the most feared complications from surgical intervention for BPH 
(McConnell, Barry et al. 1994), although it may be the result of BPH secondary to 
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overdistention of the bladder (overflow incontinence) or to detrusor instability. It is 
estimated to affect up to one half or more of all obstructed patients (urge incontinence) 
(McConnell, Barry et al. 1994; McConnell, Bruskewitz et al. 1998; Wein 2007). 
5.1.5 Hematuria 
Gross hematuria with clots with no other identifiable cause is common among BPH patients. 
Faubert et al, showed more than 30% of patients with microscopic or gross hematuria 
(Faubert 1998). Evidence suggests that in the patients predisposed to hematuria the micro-
vessel density in prostate is higher than in controls (Wein 2007), suggesting that vascular 
lesions can be the cause of hematuria. 
6. Diagnostic tests 
Although nowadays it is increasingly rare to find a patient with chronic renal failure from 
chronic urinary retention due to BPH, about 13,6% (range from 0,3 to 30%) of men with BPH 
may present with CKD defined by a baseline serum creatinine of more than 133 mmol/L 
(1,5 mg/dL). This is particularly true in older patients with cognitive deterioration and 
autonomy impairment. In order to diagnose and monitor the impact of a bladder outlet 
obstruction due to BPH in the upper urinary tract, some laboratory and imaging tests 
should be considered: standardized questionnaires, serum creatinine levels or estimated 
glomerular filtration rate (eGFR), urinalysis, serum prostatic specific antigen (PSA) levels, 
uroflowmetry with peak flow rate determination, renal ultrasonography, bladder 
ultrasonography with detrusor thickness evaluation, transrectal prostate ultrasonography, 
pre and post-void residual urinary volume, cystometry, other urodynamic studies and 
urethrocystoscopy. 
6.1 Symptom assessment by standardized questionnaires 
BPH Impact Index (BII) is a questionnaire that assesses the effect of symptoms on everyday 
life and their interference with daily activities, and thus aimes to capture the impact of the 
condition. This questionnaire can be administered in conjunction with the IPSS and provides 
useful additional information (AUA 2010). 
Symptom quantification is useful for diagnosis, determination of disease severity and 
monitoring of BPH. IPSS has become the international standard. It is derived from the 
American Urological Association Symptom Index (AUA-7 or AUA SI) described by Barry 
and colleagues in 1992 (Barry, Fowler et al. 1992; Barry, Fowler et al. 1992). 
A recent multivariate analysis conducted by Hong et al., found associations of individual 
symptoms from the IPSS questionnaire and CKD status – obstruction-related symptoms, e.g. 
weak stream and hesitancy were significantly associated with CKD in age and comorbidity-
adjusted analyses (Hong, Oh et al. 2010). Irritative symptoms, on the other hand, had no 
positive correlation with CKD. According to a subsample from the Olmsted County Study, 
moderate to severe LUTS (IPSS > 7) were positively correlated with CKD (Rule, Lieber et al. 
2005). Kidney failure risks were 2.60 (CI 95%, 1.47-4.58) and 4.08 (CI 95%, 1.74-9.53) times 
higher for men with moderate and severe LUTS compared with men with no or mild LUTS, 
respectively (p<0,001) (Hallan, Kwong et al. 2010). However, after adjusting for age and  
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Incomplete emptying 
Over the past month, how often have you had a 
sensation of not emptying your bladder completely after 
you finish urinating? 
0 1 2 3 4 5 
Frequency 
Over the past month, how often have you had to urinate 
again less than two hours after you finished urinating? 
0 1 2 3 4 5 
Intermittency 
Over the past month, how often have you found you 
stopped and started again several times when you 
urinated? 
0 1 2 3 4 5 
Urgency 
Over the last month, how difficult have you found it to 
postpone urination? 
0 1 2 3 4 5 
Weak stream 
Over the past month, how often have you had a weak 
urinary stream? 
0 1 2 3 4 5 
Straining 
Over the past month, how often have you had to push or 
strain to begin urination? 
0 1 2 3 4 5 
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Nocturia 
Over the past month, many times did you most typically 
get up to urinate from the time you went to bed until the 
time you got up in the morning? 
0 1 2 3 4 5 
Total IPSS Score  
Table 1. International Prostate Symptom Score (IPSS). 
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Quality of life due to urinary symptoms 
If you were to spend the rest of your life with 
your urinary condition the way it is now, how 
would you feel about that? 
0 1 2 3 4 5 6 
Table 2. Additional Question evaluating quality of life. 
Total score:  
0-7 Mildly symptomatic 
8-19 Moderately symptomatic 
20-35 Severely symptomatic 
therefore in isolation, IPSS is not a basis for kidney failure screening (Hallan, Kwong et al. 
2010). Kidney function decreases with age and age significantly correlates with LUTS. 
Ponholzer A. et al also concluded that LUTS was not associated with increased loss of 
kidney function (Ponholzer, Temml et al. 2006). 
Even though symptom score assessment do not directly correlates with CKD or can’t be 
used to establish the diagnosis of BPH, it may serve as a basis for symptom severity and 
management approach to patients with LUTS. Further testing should be considered in 
patients with an IPSS score ≥ 8. 
6.2 Serum creatinine 
For decades, medical textbooks have stated that patients with BPH should have serum 
creatinine measured (Humes 2000; Goldman 2008). Clinical practice guidelines disagree on 
serum creatinine screening among men being evaluated for LUTS. The routine measurement 
of serum creatinine levels is not indicated in the initial evaluation according to the AUA 
Guideline Management of BPH (AUA 2010). This recommendation is based on the 
conclusion that baseline renal insufficiency appears to be no more common in men with 
BPH than in men of the same age group in the general population. On the other hand, the 
EAU Guidelines on BPH (2004) and the nephrology-focused NICE (National Institute for 
Health and Clinical Excellence) guidelines for the United Kingdom advocate that it is 
probably cost effective to measure serum creatinine levels in all patients. This is based on 
the fact that bladder outlet obstruction due to BPH might cause hydronephrosis and renal 
failure (Sacks, Aparicio et al. 1989).  
Patients with BPH and renal insufficiency have much higher postoperative complications (25% 
complication rate compared with 17% for patients without the condition) and mortality (up to 
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sixfold) than those with normal renal function (Holtgrewe and Valk 1962; Melchior, Valk et al. 
1974; Mebust, Holtgrewe et al. 2002). Most studies have found that the incidence of azotaemia 
in men with BPH varies from 15-30% (Mukamel, Nissenkorn et al. 1979). The Agency for 
Health Care Policy and Research (AHCPR) and the Fourth International Consultation on BPH 
highly recommends serum creatinine evaluation (McConnell, Barry et al. 1994). MTOPS data 
suggest that creatinine measurement is not necessary if voiding is normal. Estimated 
glomerular filtration rate (eGFR) is a more reliable measure to define CKD and is preferred 
over simple creatinine measurement (Roehrborn 2008). 
6.3 Urinalysis 
Urinalysis is a simple and inexpensive test that is recommended for the primary evaluation 
of a patient with suspected BPH. It is used to rule out urinary tract infection and hematuria. 
On the other hand, the finding of proteinuria/microalbuminuria may be indicative of renal 
failure.  
6.4 Total PSA 
Total PSA should be offered to patients with more than 10 years of life expectancy and in 
whom the PSA measurement may change the management of the symptoms (AUA 2010). In 
conjunction with digital rectal examination (DRE), total PSA measurement is the 
cornerstone of prostatic basic screening. PSA and prostatic volume can be used to evaluate 
the risks of either needing surgery or developing acute urinary retention. 
6.5 Uroflowmetry / Peak urinary flow rate 
Uroflowmetry is a simple and noninvasive urodynamic test that allows an objective evaluation 
of the patient micturition. Even though uroflowmetry is an unspecific evaluation, the 
micturition graphic may show some recognizable patterns (e.g. meatal stenosis, urethral 
stricture, BPH) and represent a reproducible way to quantify the strength of the urinary 
stream. It is a useful preoperative test. Peak urinary flow rate (PFR), or Qmax, appears to 
predict surgical outcome – patients with a preoperative Qmax > 15 mL/s have poorer 
outcomes than patients with preoperative Qmax < 15 mL/s do. PFR is an independent 
predictor for CKD rather than reported LUTS by standardized questionnaires (Hong, Lee et al. 
2010). A study conducted by Rule et al. in community-dwelling men showed that men with 
CKD were more likely to have a slow urinary stream (Qmax < 15 mL/s) considering CKD as 
serum creatinine > 133 μmol/L or as eGFR < 60 mL/min/1,73 m2. (Rule, Jacobson et al. 2005). 
 
Fig. 1. Uroflowmetry. A) Normal patient; B) BPH patient. 
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6.6 Renal ultrasonography 
Koch et al., performed renal ultrasound scans in a consecutive series of 556 elderly men with 
LUTS. 14 (2.5%) had hydronephrosis and serum creatinine levels appeared to be correlated 
with dilatation of the renal pelvis. The authors concluded that renal ultrasound is only 
indicated in patients with an elevated serum creatinine level and/or post-void residual 
urine volume (Koch, Ezz el Din et al. 1996). Renal ultrasonography has many advantages 
over intravenous urography (IVU) for upper urinary tract imaging: simultaneous evaluation 
of the bladder, post-void residual urine volume and prostate, better characterization of 
eventual renal masses, no radiation, no side-effects and lower cost. 
   
Fig. 2. Renal Ultrassound. Two ultrasound scans in BPH patient showing bilateral (right and 
left kidney respectively) ureterohydronephrosis. 
6.7 Bladder ultrasonography 
Chronic urinary retention leads to bladder wall thickening with trabeculations via smooth 
muscle hypertrophy and connective tissue infiltrates (Jones, Gilpin et al. 1991). This can lead in 
to a decline in bladder compliance with consequent functional or mechanical obstruction at the 
ureterovesical junction (Sutaria and Staskin 2000). More recently, the measurement of bladder 
wall thickness by transabdominal ultrasound has gained considerable interest as a non-
invasive tool to assess bladder outflow obstruction (Kojima, Inui et al. 1997). Ultrasonic 
measurement of detrusor wall thickness at the anterior wall of bladders filled with ≥ 250 mL 
can securely detect bladder outlet obstruction if the value is ≥ 2 mm (Gabuev and Oelke 2011). 
   
Fig. 3. Bladder Ultrassound. Two ultrasound scans in BPH patient. It is possible to observe 
the trabecullation, bladder wall thickening and diverticulum.  
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Manieri et al. concluded that bladder wall thickness appeared to be a useful predictor of 
bladder outlet obstruction, with a value exceeding that of uroflowmetry (Manieri, Carter et 
al. 1998). However, measurement of bladder wall thickness is currently not part of the 
recommended diagnostic work-up of patients with LUTS because reliable data on inter- and 
intra-observer variability, as well as reproducibility, are still lacking. 
6.8 Post-void residual urine evaluation 
Post-void residual urine volume can be measured with sufficient accuracy noninvasively by 
transabdominal ultrasonography. The measurement variation caused by the method is less 
than the biologic range of PVR variation (McConnell, Barry et al. 1994). It may also be 
measured by invasive methods (catheterization). 
It has been well described that large residual urine volumes (>300 mL) affect renal function in 
advanced BPH (Neal, Styles et al. 1987; Rule, Jacobson et al. 2005). A PVR of more than 100 mL 
is defined as chronic urinary retention which is significantly associated with CKD in 
community-dwelling men (Rule, Jacobson et al. 2005). Nevertheless, small residual urine 
volumes (<100 mL) may also affect renal function as the presence of PVR relates with renal 
function regardless of the quantity of PVR (Yamasaki, Naganuma et al. 2011). Thus 
ultrasonographic evaluation of post-void residual is a useful test in the prevention of CKD 
secondary to BPH. Chronic urinary retention is related with CKD (Rule, Jacobson et al. 2005). 
6.9 Prostate TRUS 
Prostate transrectal ultrasonography (TRUS) is performed to assess prostate size and shape, 
tissue characterization and occult carcinoma. There is no relationship between prostatic 
enlargement measures and CKD (Rule, Jacobson et al. 2005). 
 
Fig. 4. Prostate Ultrassound.  Prostate transrectal ultrasonography (sagital view). 
6.10 Cystometry 
It is not a routine exam for BPH evaluation. However, cystometry can help to identify high 
bladder pressure, low bladder compliance and detrusor instability that considerably affects 
renal function (Rule, Lieber et al. 2005; Yamasaki, Naganuma et al. 2011). 
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6.11 Pressure-flow studies 
Pressure-flow studies can differentiate between patients with a low Qmax secondary to 
obstruction and those whose low Qmax is caused by a decompensated or neurogenic 
bladder. They are most useful for distinguishing between bladder outlet obstruction and 
impaired detrusor contractility. 
6.12 Urethrocystoscopy 
Urethrocystoscopy should not be done routinely but is optional during later evaluation if 
invasive treatment is strongly considered (McConnell, Barry et al. 1994). Nevertheless, it is a 
useful preoperative procedure to plan the most appropriate approach. This investigation 
can confirm causes of outflow obstruction while eliminating intravesical abnormalities. 
7. Treatment 
Patients with mild symptoms are most appropriately managed by watchful waiting, patients 
with moderate symptoms should receive pharmacotherapy and patients with severe bother 
most benefit from surgical management. A man with preoperative IPSS ≥ 17 has an 87% 
chance of experiencing a substantial symptom reduction (Meigs, Mohr et al. 2001). 
A group of patients at increased risk of progression can be identified on the basis of specific 
risk factors (e.g. age, symptoms, PSA level, Qmax, prostate volume and post-void residual 
urine). It might be appropriate to identify these patients at risk of progression and initiate 
early preventative treatment (Emberton et al., 2003)(Gabuev and Oelke 2011). For example, a 
higher frequency of kidney failure in patients presenting for prostate surgery than for 
nonprostate surgery has been shown, and several studies have shown improvement in 
kidney function after prostatectomy (Hill et al., 1993). 
7.1 Acute treatment 
Patients who present to the emergency department with bladder outlet obstruction and high 
serum creatinine should receive a urethral catheter and subsequently evaluated in order to 
distinguish between acute and chronic renal failure. Hospitalization is often required in 
these cases. If ureterohydronephrosis and azotaemia persists despite bladder 
desobstruction, an ureterovesical junction obstruction should be considered and bilateral 
percutaneous nephrostomy or bilateral ureteric stents (if feasible) are advisable for 
temporarily drainage. Patients may need urgent and transitory dialysis.  
Neoureterocystostomy after a prostate ablative procedure may be adequate for definite 
ureterovesical junction obstruction resolution. 
7.2 Watchful waiting 
Watchful waiting (WW) is an appropriate strategy for men who are not bothered by their 
symptoms and have not developed BPH related complications.  
This option should include education, reassurance, periodic monitoring and lifestyle advice 
to the patient. Lifestyle counseling include: reduction of fluid intake during specific times 
for control of urinary frequency (e.g. at night or when going out in public) but not of the 
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total amount of daily fluid (above 1500 mL per day), avoidance of alcohol and caffeine 
because they have diuretic and irritant effect, bladder retraining to increase its capacity and 
constipation treatment. Watchful waiting is based on the notion that some symptoms may 
spontaneously improve whilst others may remain stable for years. The PSA level and the 
prostate volume may be helpful in predicting the risk of acute urinary retention, although 
they should not be used as a sole determinant for active therapy (Levy and Samraj 2007). 
Approximately 85% of men will be stable on WW at 1 year, deteriorating progressively to 
65% at 5 years (Wasson, Reda et al. 1995; Netto, de Lima et al. 1999). This approach is not 
suitable for men with installed CKD due to bladder outlet obstruction. 
7.3 Medical treatment 
Medical approaches are not used to treat BPH complications (in which CKD is included). 
They are used for LUTS relief and for prevention of BPH progression (especially 5 alpha 
reductase inhibitors - 5-ARI).  
7.3.1 Alpha-blockers 
Alpha-blockers address the dynamic component of prostatic obstruction by antagonizing 
the adrenergic receptors responsible for smooth muscle tone within the stroma, prostate 
capsule and bladder neck, providing the most rapid symptom relief. They include: 
terazosin, doxazosin, alfuzosin, tamsulosin and silodosin. These drugs have similar efficacy 
but different patterns of side-effects: 
 
Alpha-
Blocker 
Dosage Side-effects 
Terazosin 
1 mg once a day 
May increase up to 20 mg a day 
Asthenia, hypotension, dizziness, 
somnolence 
Doxazosin 
1 mg once a day 
May increase up to 8 mg once daily 
Orthostatic hypotension, fatigue and 
dyspnea 
Alfuzosin 10 mg once a day 
Fatigue, edema, rhinitis, headache, 
upper respiratory tract infection 
Tamsulosin 0,4 mg once a day Dizziness, rhinitis, abnormal ejaculation 
Silodosin 
8 mg once a day 
4 mg once a day for men with 
moderate kidney dysfunction 
Diarrhea, headache and commons cold 
symptoms, nasal congestion, retrograde 
ejaculation (the most common) 
Table 3. Alpha blockers used, dosage and side-effects. 
The older, less costly, generic alpha blockers remain reasonable choices. However, these 
require dose titration and blood pressure monitoring. Alpha-blockers are the most 
prescribed medications for BPH as long as they have a rapid (symptoms may improve in 48 
hours) and significant improvement on LUTS.  
7.3.2 5-alpha-reductase inhibitors 
5-Alpha-Reductase Inhibitors (5-ARI) are anti-androgenic hormonal agents that address the 
static component of BPH by reducing the prostate volume (up to 20-30%). They include 
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finasteride and dutasteride and are more effective in prostates larger than 40 mL (Boyle, 
Gould et al. 1996). According to some trials, finasteride significantly reduced acute urinary 
retention and the need for surgical treatment in men with BPH.  
5-ARIs are the only pharmacologic treatment that may be used to prevent progression of 
LUTS secondary to BPH and to reduce the risk of urinary retention and future prostate-
related surgery. Therefore, indirectly, it may be useful in preventing BPH complications 
such as chronic kidney failure. However, they can’t revert CKD related to BPH after 
installed.  
 
5-Alpha-Reductase 
Inhibitor 
Dosage Side-effects 
Finasteride 5 mg once a day Erectile dysfunction, decreased 
libido, decreased serum PSA, 
gynecomastia 
Dutasteride 
1 mg once a day 
May increase up to 8 mg once daily 
Table 4. 5 alpha-reductase inhibitors used, dosage and side-effects. 
Finasteride inhibits exclusively the 5-AR type II isoenzyme, while dutasteride inhibits both 
types I and II. This difference in activity leads to a reduction in serum levels of 
dihydroxytestosterone (DHT) by approximately 70% with finasteride compared to 
approximately 95% with dutasteride (Clark, Hermann et al. 2004). 
Finasteride (and probably dutasteride) is an appropriate and effective treatment alternative 
in men with refractory hematuria presumably due to prostatic bleeding (Foley, Soloman et 
al. 2000; Kearney, Bingham et al. 2002; Perimenis, Gyftopoulos et al. 2002). 
7.3.3 Combination therapy 
The Medical Therapy of Prostate Symptoms (MTOPS) Study demonstrated that in the long 
term, among men with larger prostates, combination therapy is superior to either alpha-
blocker or 5-ARI therapy in preventing progression and improving symptoms (McConnell, 
Roehrborn et al. 2003). 
7.3.4 Phytotherapy 
The use of plant-derived agents (Serenoa repens or Saw palmetto, Pygeum africanum) on LUTS 
and BPH has been popular in Europe for many years and has recently spread in the USA. 
Their mechanism of action is still unclear. However they seem to improve urinary 
symptoms without important side effects. In some studies the efficacy of these compounds 
was found to be equivalent to 5-ARIs and alpha-blockers (Lowe 2001; Debruyne, Koch et al. 
2002).  The most widely studied and used, Serenoa repens, has no effect on prostate volume 
or the PSA test, but slightly decreases the prostate epithelium. It does not cause erectile 
dysfunction, but the herb may aggravate chronic gastrointestinal disease such as peptic 
ulcer (Bent, Kane et al. 2006). 
7.4 Surgical treatment 
Men who develop serious complications from BPH should be treated surgically in most of 
the cases. Both Agency for Health Care Policy and Research and International Consensus 
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Guidelines recommend surgery if the patient has refractory or recurrent urinary retention 
(failing at least one attempt of catheter removal) or any of the following conditions clearly 
secondary to BPH: recurrent UTI, recurrent gross hematuria, bladder stones, renal 
insufficiency, or large bladder diverticula (McConnell, Barry et al. 1994) (Denis et al., 1998). 
Studies suggest that dialysis dependent patients may recover renal function up to a year 
after prostatic surgery. In this setting, efforts should be made to identify and treat BPH in 
patients under dialysis. 
Surgeries are associated with postoperative risks such as erectile dysfunction (4% to 10% 
incidence) and urinary incontinence (0.5% to 1.5%) (Flanigan, Reda et al. 1998) (McConnell, 
Bruskewitz et al. 1998). The 5-year recurrence rate of BPH following surgery is 2% to 
10%(Flanigan, Reda et al. 1998). Proper therapy can be offered to the right men and the costs 
of long-term renal damage and post-surgical complications can be avoided.  
7.5 Standard surgical procedures 
TURP (transurethral resection of the prostate) is the hallmark of the urologist, the one 
against which other therapeutic measures are compared. It takes 20 to 30 minutes to resects 
an average gland weighing of 30 g and carry risks  complications like bleeding, infections, 
retrograde-ejaculation, hospital stay,  impotence and incontinence. 
In patients presenting with renal failure due to bladder outflow obstruction, TURP restores 
normal voiding pattern in many cases. However renal failure due to bladder outflow 
obstruction tends to be more refractory and 57% of patients in Thomas et al. study were 
dialysis dependent after surgery. Only 3 of 14 patients experienced return to normal renal 
function post TURP (Thomas, Thomas et al. 2009).  
Mortality following prostatectomy has decreased significantly within the past two decades 
and is less than < 0.25% in contemporary series (Holman, Wisniewski et al. 1999; Hahn, 
Farahmand et al. 2000). The risk of a TUR-syndrome (fluid intoxication, serum Na+<130 
nmol/L) is in the range of 2%. Risk factors for the development of the TUR-syndrome are 
excessive bleeding with opening of venous sinuses, prolonged operation time, large glands 
and past or present smoking. 
Open prostatectomy is the treatment of choice for large glands (>80-100 mL), bladder stones 
or if resection of bladder diverticula is indicated. Open prostatectomy involves the surgical 
removal (enucleation) of the inner portion of the prostate via a suprapubic or retropubic 
prostatectomy.  
7.6 Minimally invasive surgical therapies 
Standard operations are TURP in small (≤80-100mL) or open prostatectomy in large 
prostates (>80-100mL). Minimally invasive, alternative surgeries may be considered in 
selected men and offer advantages regarding risk of bleeding, duration of catheterization, or 
maintenance of sexual function. (Gabuev and Oelke 2011). 
Transurethral incision of the prostate (TUIP) or bladder neck incision is recommended for 
smaller gland (weigh <25g) and has been found to be less invasive than TURP (Orandi 
1990). TUIP has several advantages over TURP, such as a lower incidence of complications, 
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minimal risk of bleeding and blood transfusion, decreased risk of retrograde ejaculation, 
shorter operating time and hospital stay, and an importantly higher long-term failure rate. 
Transurethral electrovaporization (TUVP) is a modification of TURP and TUIP, employing 
high electrical current to vaporize and coagulate the obstructive prostate tissue. Long-term 
efficacy is comparable with TURP, but high number of patients has been found to 
experience irritative side effects (Desautel, Burney et al. 1998). 
Transurethral needle ablation (TUNA) is a simple and relatively inexpensive procedure which 
uses a needle to deliver high-frequency radio waves to destroy the enlarged prostatic tissue. 
TUNA is a successful treatment for small-sized gland and it poses a low or no risk for 
incontinence and erectile dysfunction (Ramon, Lynch et al. 1997). 
Transurethral microwave thermotherapy (TUMT) heats the prostate using a microwave 
antennae mounted on a urethral catheter (Thorpe and Neal 2003). TUMT has been found to 
be safe and cost effective, with reasonable improvement in urine flow rate and minimal 
impairment on sexual function (Richter, Rotbard et al. 1993). 
Transurethral ethanol ablation of the prostate (TEAP) has been recently introduced as a 
minimally invasive alternative treatment for patients with BPH. TEAP produces necrotic 
effect on prostatic tissues, leading to fibrosis and shrinkage. It is an effective minimally 
invasive treatment option for medically high-risk symptomatic patients with BPH that can 
be performed as an outpatient procedure under regional anesthesia (El-Husseiny and 
Buchholz 2011). 
Laser prostatectomy: four types of lasers have been used to treat LUTS, namely neodymium: 
yttrium-aluminum-garnet (Nd: YAG) laser, holmium YAG laser (Ho:YAG), potassium 
titanyl phosphate (KTP), and diode laser. It has been found to be safe and effective 
technique, with significant improvement in urinary flow rates and symptoms. Short surgery 
time, shorter catheter use, minimal blood loss and fluid absorption, decreased hospital stay, 
low erectile dysfunction rates, and bladder neck contractures are few of the advantages of 
laser prostatectomy over the TURP and other conventional techniques (Donovan, Peters et 
al. 2000; Bent, Kane et al. 2006). Laser surgery is specially indicated in patients receiving 
anticoagulant therapy that want to maintain ejaculation or are unfit for TURP. 
Transrectal HIFU (high intensity focus ultrasonography) therapy is the only technique that 
provides non-invasive tissue ablation; however, general anesthesia or at least heavy 
intravenous sedation is required. Long-term efficacy is limited, with a treatment failure rate 
of approximately 10% per year.Significant increase in uroflow and a decrease in postvoid 
residual volume have been observed, but the cost is three times higher than that of TURP 
(Madersbacher, Kratzik et al. 1993). 
8. Future approaches to BPH  
Increasing average life expectancy, especially due to better health care and better education 
of the population, make us believe that soon we shall have, seek for medical care,   a greater 
number of people suffering from elderly diseases.  The health burden of disorders such as 
BPH will be a major dome for research in the future. 
Recent investigation is underway in this field, some basic and translational research is being 
done, in an attempt to better understand and treat this prevalent disease. 
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Recently Woo et. al reported the use of a Prostatic Urethral Lift (PUL) procedure, which is a 
novel, minimally invasive treatment for symptomatic benign prostatic hyperplasia (BPH).  
PUL aims to mechanically open the prostatic urethra without ablation or resection, with 
patients reporting sustained symptom relief for 12 months with minimal morbidity (Woo, 
Chin et al. 2011).  
Tadalafil and other phosphodiesterase type 5 (PDE5) inhibitors have demonstrated 
beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell 
proliferation, nerve activity, and tissue perfusion that may impact LUTS (Andersson, de 
Groat et al. 2011). Consistent evidence of improvements in LUTS has been shown with 
PDE5-Is, either alone or in combination with ǂ-blockers (Martinez-Salamanca, Carballido et 
al. 2011). However, urodynamic results or objective measures of urinary flow are lacking 
(Martinez-Salamanca, Carballido et al. 2011). 
De Souza et al, investigated the effects of Orbignya speciosa, a nanoparticle extract, newly 
developed phytotheraphy that can be safely used on the management of BPH (de Souza, 
Palumbo et al. 2011). 
In our country (Portugal) a recent study led by Pisco et. al, aimed to evaluate whether 
prostatic arterial embolization could be a feasible way to treat lower urinary tract symptoms 
associated with benign prostatic hyperplasia. Their preliminary results and short-term 
follow-up suggest good symptom control without sexual dysfunction associated with a 
reduction in prostate volume (Pisco, Pinheiro et al. 2011). 
Rick et al, in recent times used growth hormone-releasing hormone (GHRH) in animal 
models. They concluded that GHRH antagonists can lower prostate weight in experimental 
BPH with significant reductions in protein levels of IL-1ǃ, NF-κǃ/p65, and cyclooxygenase-
2 (COX-2), suggesting that GHRH antagonists should be considered for further investigation 
as therapy for BPH (Rick, Schally et al. 2011) 
It is important in a near future to characterize a clinical phenotype of BPH; measure disease 
severity and outcomes; design clinical trials; study concepts for drug therapy, behavioral 
and lifestyle interventions and additional intervention therapies (AUA 2010). 
9. Conclusion 
Benign prostatic hyperplasia and chronic kidney disease are two common and prevalent 
entities in elderly men. It has been reported in several studies that threads of evidence 
suggest that BPH is a risk factor for chronic kidney disease. An average of 13,6% patients 
presenting to urologic clinics for the treatment of BPH had renal failure. The low occurrence 
of CKD in BPH clinical trials should not be used to infer a weak association between these 
two disease processes (Rule et al., 2005). From our own experience we deem that the average 
of patients with BPH and some degree of renal disease can be higher, mostly because older 
men most of the times ignore their micturition problems and seek for clinical help just in a 
later degree of BPH. 
Although BPH is not a life-threatening condition, the impact BPH on quality of life (QoL) 
can be significant and should not be underestimated. On the other hand CKD is an 
important medical problem that can even be critical (Fox, Larson et al. 2004) 
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It has been well documented that bladder outlet obstruction by an enlarging prostate can 
lead to renal insufficiency. Relationship between symptoms severity and elevated serum 
creatinine in men with BPH have not been well defined.  Recent data make us believe that  
combination of all these factors leading to  chronic and progressive urinary retention, high 
bladder pressure, ureterohydronephrosis work together causing progressive renal injury.  
Obstructive process root cellular and physiological changes in bladder muscle and collagen, 
contribute to a high pressure bladder that perpetuates itself with worsening ability to empty 
and causing kidney lesions leading to renal failure. 
The advent of medical treatment has obviated the need for surgery in many patients with 
BPH. Men in acute urinary retention or those with urinary tract infection and other BPH-
complications, may benefit from more aggressive BPH treatment to prevent renal failure, 
especially if the conditions are recurrent. 
Other kidney risk factors such as diabetes mellitus, cardiovascular disease, hypertension, 
obesity and dyslipidemia may also be considered in the patient with BPH. Etiology of CKD 
is often multifactorial and BPH may accelerate the progression of CKD in other disease 
processes. 
Older men with BPH often tolerate and ignore lower urinary tract symptoms and may not 
present for medical consultation until they develop uremic syndrome. Thus, these patients 
should have prostatic obstruction considered during evaluation and treatment as this 
diagnosis can be easily missed in unreported LUTS. Close follow-up is mandatory.  
We emphasize that CKD secondary to BPH is a preventable disease, and if early detected 
can prevent costs of CKD treatment (including hemodialysis) with considerable saves 
(economic, health care, social).   
Findings that we mentioned in this chapter suggest that progressive nephropathy caused by 
prostatic/bladder outflow obstruction – urinary outflow obstruction – might be averted by 
more adequate screening of renal function in men with untreated BPH. 
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